caa a22 4500 469120967 CHVBK 20180323133138.0 cr unu---uuuuu 170328e19920601xx s 000 0 eng 10.1007/BF02245276 doi (NATIONALLICENCE)springer-10.1007/BF02245276 Role of sodium cromoglycate on analgesia, locomotor activity and opiate withdrawal in mice [Elektronische Daten] [Juan-Carlos Leza, Ignacio Lizasoain, Olivia San Martín-Clark, Pedro Lorenzo] The role of sodium cromoglycate (CRO) on analgesia, locomotor activity and morphine withdrawal in mice was studied in morphine-dependent and drugnaive mice. CRO (0.5, 1, 5, 10, 30, 50 and 100 mg/kg, SC) induces analgesia (hot plate), an effect blocked by previous administration of the opiate antagonist naloxone (1 mg/kg). Furthermore, CRO (30 mg/kg) potentiates morphine analgesia. In morphine-tolerant mice, moderate doses of CRO (0.5, 1, 5, 10 and 30 mg/kg) do not induce analgesia, which suggested the development of cross tolerance between CRO and morphine, whereas coadministration of CRO and morphine in morphine tolerant animals restored the sensitivity to morphine. Administration of CRO (10 and 30 mg/kg) induces an increase in spontaneous locomotor activity, and previous administration of naloxone (1 mg/kg) blocks this effect, whereas CRO (10 mg/kg) blocks morphine (10 mg/kg) and amphetamine (3 mg/kg)-induced hyperactivity. CRO (10, 50 and 100 mg/kg) induces a significant and dose-dependent reduction in the number of jumps ("jumping up”) during naloxone (1 mg/kg)-induced withdrawal in morphine-dependent mice. Finally, CRO (100 mg/kg) reduces the "wet dog shake” phenomenom during naloxone-induced withdrawal in morphine-dependent mice. These results suggest a possible stabilizing effect of CRO on the membranes of neurones that mediate analgesia, locomotor activity and opiate abstinence. Changes and inhibition of DA, NA and 5-HT release may also explain these effects. Springer-Verlag, 1992 Analgesia nationallicence Locomotor behavior nationallicence Opiate withdrawal nationallicence Sodium cromoglycate nationallicence Leza Juan-Carlos Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, E-28040, Madrid, Spain aut Lizasoain Ignacio Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, E-28040, Madrid, Spain aut San Martín-Clark Olivia Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, E-28040, Madrid, Spain aut Lorenzo Pedro Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, E-28040, Madrid, Spain aut Psychopharmacology Springer-Verlag 107/4(1992-06-01), 595-600 0033-3158 107:4<595 1992 107 213 https://doi.org/10.1007/BF02245276 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02245276 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Leza Juan-Carlos Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, E-28040, Madrid, Spain aut NATIONALLICENCE 700 1- Lizasoain Ignacio Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, E-28040, Madrid, Spain aut NATIONALLICENCE 700 1- San Martín-Clark Olivia Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, E-28040, Madrid, Spain aut NATIONALLICENCE 700 1- Lorenzo Pedro Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, E-28040, Madrid, Spain aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 107/4(1992-06-01), 595-600 0033-3158 107:4<595 1992 107 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer